Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Group 1 - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone [1][3] - The company will report its financial results for the third quarter ended September 30, 2024, on November 11, 2024, after market close [1] - The initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor targeting cardiorenal conditions [3] Group 2 - A live webcast of the conference call regarding the financial results will be available on the company's Investor Relations page [2] - Contact information for investor relations and media relations is provided for further inquiries [4]